KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gains from Sales and Divestitures: 2012-2015

  • Alnylam Pharmaceuticals' Gains from Sales and Divestitures fell 68.11% to $159,122 in Q4 2015 from the same period last year, while for Dec 2015 it was $159,122, marking a year-over-year decrease of 68.11%. This contributed to the annual value of $159,122 for FY2015, which is 68.11% down from last year.
  • Alnylam Pharmaceuticals' Gains from Sales and Divestitures amounted to $159,122 in Q4 2015, which was down 68.11% from $499,000 recorded in Q4 2014.
  • In the past 5 years, Alnylam Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $499,000 in Q4 2014 and a low of $105,093 during Q4 2013.
  • Its 3-year average for Gains from Sales and Divestitures is $254,405, with a median of $159,122 in 2015.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Gains from Sales and Divestitures spiked by 374.82% in 2014, and later slumped by 68.11% in 2015.
  • Alnylam Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $141,740 in 2012, then decreased by 25.86% to $105,093 in 2013, then soared by 374.82% to $499,000 in 2014, then slumped by 68.11% to $159,122 in 2015.
  • Its last three reported values are $159,122 in Q4 2015, $499,000 for Q4 2014, and $105,093 during Q4 2013.